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Sciences, Linköping University, Linköping, SwedenA B S T R A C TBackground: There is limited information on drivers of utilities in
patients with chronic heart failure (CHF). Objectives: To analyze
determinants of utility in CHF and drivers of change over 1 year in a
large sample from clinical practice. Methods: We included 5334
patients from the Swedish Heart Failure Registry with EuroQol ﬁve-
dimensional questionnaire information available following inpatient
or outpatient care during 2008 to 2010; 3495 had 1-year follow-up data.
Utilities based on Swedish and UK value sets were derived. We
applied ordinary least squares (OLS) and two-part models for utility
at inclusion and OLS regression for change over 1 year, all with robust
standard errors. We assessed the predictive accuracy of both models
using cross-validation. Results: Patients’ mean age was 73 years, 65%
were men, 19% had a left ventricular ejection fraction of 50% or more,
23% had 40% to 49%, 27% had 30% to 39%, and 31% had less than 30%.
For both models and value sets, utility at inclusion was affected by
sex, age, New York Heart Association class, ejection fraction,ee front matter & 2015 Published by Elsevier Inc.
(ISPOR).
.1016/j.jval.2015.02.003
rg@ki.se.
ondence to: Jenny Berg, Karolinska Institutet, Insthemoglobin, blood pressure, lung disease, diabetes, angiotensin-
converting enzyme inhibitors/angiotensin receptor blockers, nitrates,
antiplatelets, and diuretics. The OLS model performed slightly better
than did the two-part model on a population level and for capturing
utility ranges. Change in utility over 1 year was inﬂuenced by age, sex,
and (measured at inclusion) disease duration, New York Heart
Association class, blood pressure, ischemic heart disease, lung dis-
ease, angiotensin-converting enzyme inhibitors/angiotensin receptor
blockers, and antiplatelets. Conclusions: Utilities in CHF and their
change over time are inﬂuenced by diverse demographic and clinical
factors. Our ﬁndings can be used to target clinical interventions and
for economic evaluations of new therapies.
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Chronic heart failure (CHF) is associated with high morbidity
and mortality, as well as large reductions in health-related
quality of life (HRQOL) [1,2]. Although the incidence and the
mortality of CHF have generally decreased over time, disease
burden remains high due to a signiﬁcant need for specialized
and hospital care [2,3]. As new treatment strategies are emerg-
ing for CHF, for both patients with preserved and with reduced
left ventricular ejection fraction (LVEF) [4], it is important to be
able to evaluate these therapies in terms of their clinical beneﬁt
and cost-effectiveness.In economic evaluations, effectiveness outcomes are gener-
ally measured using quality-adjusted life-years, an aggregate
measure for length and quality of life. Quality-adjusted life-years
are calculated by weighing survival with a utility score between
0 and 1, where 1 represents perfect health and 0 death (or a
health state equivalent to death in the eyes of the respondent).
Utilities can be derived from responses to generic HRQOL instru-
ments through algorithms based on different valuation methods
(e.g., time trade-off or standard gamble) [5]. Values for different
health states derived from, for example, the generic EuroQol ﬁve-
dimensional questionnaire (EQ-5D) instrument are commonly
referred to as value sets; an important distinction lies in whetheron behalf of International Society for Pharmacoeconomics and
itute of Environmental Medicine, Box 210, SE-171 77 Stockholm,
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the health state (experience-based values) or from individuals
from the general population to whom the health states are
described (hypothetical values) [6].
Understanding the determinants of utility in a patient group
allows adjusting for differences in populations when combining
diverse data sources in economic models. Moreover, it provides
information on factors that may be inﬂuenced through patient
management. The strong link between HRQOL in CHF and
morbidity and mortality makes it particularly important to
understand which factors have an impact on utility as an
aggregate measure of HRQOL (e.g., [7–9]). Independent determi-
nants of HRQOL in CHF include age, sex, New York Heart
Association (NYHA) class, LVEF, clinical parameters, comorbid-
ities, medications, and previous hospitalizations [10–14]. To our
knowledge, however, the only published utility function available
in CHF to date is based on the Eplerenone Post-Acute Myocardial
Infarction Heart Failure Efﬁcacy and Survival Study [12], in which
HRQOL was modeled on the basis of the EQ-5D. Thus, there is a
need for analyses based on clinical practice, taking into account a
wide range of demographic and clinical parameters. The main
objective of our study was to analyze the impact of different
determinants on utilities in CHF, including a range of demo-
graphic and clinical parameters, and to analyze the impact of
different factors on change in utility over 1 year.Methods
Study Population
The Swedish Heart Failure Registry (SHFR) was created in 2003
with the goal of improving the management of patients with CHF
[15]. Patients are included at discharge from hospital (within 1
month) or following an outpatient visit, and registered variables
include demographic characteristics and disease information,
comorbidities, diagnostic procedures, hemodynamics, laboratory
data, medications, CHF symptoms, and HRQOL. After 1 year, all
patients receive a questionnaire on HRQOL, functional capacity,
and current medications [15]. In 2010, 84% of Swedish hospitals
and 6% of Swedish primary care units were reporting into the
SHFR. By the end of 2010, 36911 patients had been included in the
registry, corresponding to an estimated mean patient coverage of
61% among participating hospitals [16].
In the SHFR, the HRQOL has been measured with the EQ-5D as
part of the 1-year follow-up since 2005, and as part of baseline
registrations since 2008. The EQ-5D covers ﬁve dimensions of
health: mobility, self-care, usual activities, pain/discomfort, and
anxiety/depression, as well as a visual analogue scale. In the
established three-level version, each attribute can be described as
causing no problems, some problems, or major problems [17].
We obtained data for all patients included in the SHFR until
December 31, 2010, who had responded to the EQ-5D at either
inclusion and/or 1-year follow-up. Comparisons between those
with complete EQ-5D information and the overall registry were
made using the 2010 annual report from the SHFR [16]. To
describe the impact of CHF on HRQOL relative to the general
population, the EQ-5D responses were compared with published
Swedish population values [18].
Statistical Methods
Variable Deﬁnitions
Answers to the EQ-5D were translated into utilities by using a
recently published value set for Sweden, which uses experience-
based preferences [6]. The main analysis thus reﬂects preferences
in the same local context as the SHFR. Because generalpopulation preferences are used in several jurisdictions, secon-
dary results are also presented on the basis of the commonly
used UK value set [19].
Age was transformed into a categorical variable using 10-year
age bands (o60 years, 60–69 years, 70–79 years,Z80 years), which
are most often used in the literature. Inpatient setting was deﬁned
as during or subsequent to an inpatient stay, including those
referred to a heart failure clinic/care team, and outpatient setting
as involving outpatient specialists or primary care physicians.
The glomerular ﬁltration rate was estimated on the basis of the
Modiﬁcation of Diet in Renal Disease equation [20].
Covariate Selection Process
Variables were selected for testing on the basis of expected
clinical relevance and ﬁndings from previous studies and
included age group, sex, point of care (inpatient/outpatient),
duration of CHF (o6 months or ≥6 months), NYHA class reported
by the clinician at inclusion, comorbidities (hypertension, atrial
ﬁbrillation, diabetes, lung disease, ischemic heart disease, valv-
ular heart disease, dilated cardiomyopathy), LVEF (Z50%, 40%–
49%, 30%–39%,o30%), systolic blood pressure (SBP), heart rate,
estimated glomerular ﬁltration rate, hemoglobin, performed pro-
cedures (cardiac revascularization, device therapy, cardiac valv-
ular surgery), and medications at inclusion (angiotensin-
converting enzyme [ACE] inhibitors/angiotensin receptor blockers
[ARBs], beta-blockers, diuretics, aldosterone antagonists, digitalis,
statins, long-acting nitrates, antiplatelets). Potential explanatory
variables with strong correlations (Pearson’s r Z 0.6) were
excluded from further regression analyses to avoid multicolli-
nearity. Each candidate predictor was examined individually
using univariate regression models with robust standard errors.
Variables statistically signiﬁcant at the P o 0.1 level in univariate
analyses were included in subsequent multivariate regressions;
based on clinical rationale, age and sex were always retained. For
the change analysis, all signiﬁcant drivers of baseline utility were
included in the initial multivariate model. The ﬁnal models were
based on covariates signiﬁcant at the P o 0.05 level.
Model Selection and Speciﬁcation: Baseline Utility
Because of their boundedness and a common ceiling effect (often
with a “spike” at the upper bound for the EQ-5D), utilities do not
follow the distributional assumptions required to make an
inference about the signiﬁcance of coefﬁcients from ordinary
least squares (OLS) regression. Given our research objective, that
is, to determine drivers of mean utility in a population that can
also be used in economic evaluations, and the relative ease of
interpretation of outputs, we used OLS with robust standard
errors as the main approach [21,22]. In view of the high propor-
tion of values at the ceiling (0.97/1 using the Swedish/UK value
set), however, we also tested two-part models as an alternative
method frequently discussed in the literature [21,23]. The ﬁrst
part predicts the probability of an individual obtaining the EQ-5D
ceiling value by using logistic regression, and the second part
models the EQ-5D index value for those whose scores are below
the ceiling using OLS regression. For both regression steps, robust
standard errors were used. All covariates found to be signiﬁcant
in either the logistic or the OLS model were included in the ﬁnal
two-part model.
In both approaches, we tested to include the following inter-
actions in the ﬁnal models, based on clinical hypotheses and
earlier studies on determinants of HRQOL in CHF [12,24–26]: age/
sex and NYHA class, age/sex and number of comorbidities, and
age/sex/number of comorbidities and LVEF, respectively. Finally,
we performed comprehensive diagnostic testing of model ﬁt and
speciﬁcation, including scatter plots of model residuals ver-
sus ﬁtted values, goodness of ﬁt (R2 for OLS, Hosmer-Lemeshow
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eiver operating characteristic for logistic regression.
Model Validation
To assess the predictive accuracy of the OLS and two-part
modeling approaches, we performed empirical cross-validation
by randomly splitting the data set into a training (90%) and
validation (10%) set. For the two-part model, the expected utility
for a patient was calculated as described previously [23]. We
compared the predicted versus observed means on an aggregate
level (using paired Student t tests), the range of predictions, and
the errors between the actual and predicted individual utilities
(mean squared error, mean absolute error; with bootstrapped 95%
conﬁdence intervals) [27,28]. For the Swedish value set, this was
also performed by age category.
For covariates for which more than 5% of the observations
were missing, that is, NYHA class and LVEF, we performed
multiple imputations as part of a sensitivity analysis. We used
chained imputation with ordered logistic regression (m ¼ 20).
Because the largest spread of values can be expected for the UK
value set, we compared the results of the two regression models
applied to this value set by deriving utilities for hypothetical
patients from the mild and severe end of the spectrum.
Model Selection and Speciﬁcation: Change in Utility
For determinants of change in utility over 1 year, we applied OLS
regression to model the absolute change score, applying robust
standard errors to account for the high kurtosis in the outcome
distribution.
All analyses were performed in Stata/SE 10.0 (StataCorp,
College Station, TX, USA).Results
General
Baseline characteristics are presented in Table 1. At inclusion in
the registry, 5334 patients had completed the EQ-5D, which
corresponds to 14% of the patients in the SHFR at the time of
data extraction (38% of the patients included during 2008–2010).
Compared with the entire SHFR population, patients who had
completed the EQ-5D were on average slightly younger, more
often male, had more complete information on NYHA class and
slightly better renal function, and received ACE inhibitors/ARBs
more often and diuretics less often (Table 1).
At 1-year follow-up, 3495 (66%) patients in our sample had
completed the EQ-5D. Among these, mean age was 71.8 years and
utility 0.846 at inclusion; that is, loss to follow-up occurred to a
higher degree among older patients and among those with lower
baseline utility. Mean utility was 0.840  0.126 after 1 year
compared with 0.846  0.127 for the same patients at inclusion.
HRQOL in Patients with CHF Compared with the General
Population
Compared with a similar age group (70–79 years) in the Swedish
general population [18], HRQOL in patients with CHF at inclusion
was negatively affected in the domains of mobility, self-care, and
anxiety/depression, while slightly fewer patients with CHF
reported moderate or severe problems with usual activities (Fig. 1).
Determinants of Utility at Inclusion
Results of the OLS and two-part regressions for utilities based on
the Swedish value set are presented in Table 2. For both methods,
utility was affected in the same direction by sex, age, NYHA class,LVEF, hemoglobin, SBP, lung disease, diabetes, ACE inhibitors/
ARBs, nitrates, antiplatelets, and diuretics. In the OLS model,
beta-blockers were also signiﬁcant, whereas in the two-part
model, hypertension and previous revascularization were signiﬁ-
cant instead. Moreover, we found a signiﬁcant interaction
between age categories and NYHA class. The interaction implies
that patients younger than 60 years are more severely affected by
increasing NYHA status than are those older than 60 years.
Results of the OLS and two-part regressions for utilities based
on the UK value set are presented in Table 3. The same
coefﬁcients were found to be signiﬁcant, with the same direction
of change, as for the Swedish value set, except that beta-blockers
instead of previous revascularizations were signiﬁcant in the
two-part model. As shown in Table 1, utilities were markedly
higher when using the Swedish value set instead of the UK value
set, with a smaller range and an upper bound at 0.97 instead of 1.
Consequently, the magnitude of model coefﬁcients differs for the
two value sets. For applications in a Bayesian framework, the
covariance matrix for the identiﬁed covariates based on the UK
value set is available as a supplementary table (see Appendix
Table S1 in Supplemental Materials found at http://dx.doi.org/10.
1016/j.jval.2015.02.003).
Comparison of Predictive Accuracy of Models at Inclusion
Results of the cross-validation for the OLS and two-part models
are summarized in Table 4. For the Swedish value set, the mean
predicted utility was numerically closer to the observed mean
when using the OLS model, although mean absolute error and
mean squared error were slightly better for the two-part model.
Overall, the OLS model generated a somewhat broader range of
predictions, although it still did not capture the whole spectrum
of observed values. For the UK value set, the two-part model
provided slightly more precise predictions than did the OLS
model in terms of mean predicted utility (although not statisti-
cally signiﬁcant), mean absolute error, and mean squared error.
As for the Swedish value set, the predicted range was better using
the OLS model.
When analyzing predictions by age groups for the Swedish
value set, these were least precise in those younger than
60 years (data not shown). In this age group, the OLS model
produced better predictions in terms of mean and range, with
similar error to the two-part model. For those aged 60 to 69 years,
the two-part model was slightly better in terms of mean pre-
diction and error, whereas the OLS model more satisfactorily
captured especially the lower range of predictions. In those aged
70 to 79 years, the two-part model was slightly preferable to the
OLS model in terms of range and error, but with less precise
prediction of the mean. Finally, in those older than 80 years, the
two-part model performed better regarding mean prediction and
range, with a similar mean error as the OLS model. The differ-
ences in mean predictions, however, were statistically signiﬁcant
only for the two-part model in the youngest age group.
We found the predicted utilities based on the imputed data to be
very similar to the complete case regression (difference 0.01–0.02).
Determinants of Change over 1 Year
Results of the multivariate regression for change in utilities based
on the Swedish value set are presented in Table 5 (results based
on the UK value set are available in Appendix Table S2 in
Supplemental Materials found at http://dx.doi.org/10.1016/j.jval.
2015.02.003). Absolute change over 1 year for those with follow-
up information was affected by age, sex, and the following
variables at inclusion: NYHA class, disease duration, SBP, ische-
mic heart disease, lung disease, ACE inhibitors/ARBs, and
antiplatelets.
Table 1 – Baseline characteristics for patients who completed the EQ-5D at inclusion and 1-y follow-up,
compared with all patients in the SHFR (2010).
Variable All patients in
SHFR
Patients with the
EQ-5D at
inclusion
Patients with the
EQ-5D at follow-
up
Demographic characteristics
Number of patients 36,911 5,334 3,495
Age at inclusion (y) 74.8 72.9  11.4 71.8  11.0
Sex: female (%) 39 35 34
Point of care (%)
Inpatient care and referrals to outpatient heart failure
clinics
94 79 82
Outpatients in primary care and specialist care 6 21 18
Disease characteristics at discharge/after visit
Duration of heart failure (%)
o6 mo 48 49 55
Z6 mo 52 51 45
Unknown/missing NA 1 1
NYHA class (%)
I 6 10 11
II 32 44 49
III 27 33 31
IV 4 3 2
Unknown 30 9 8
LVEF (%)
Z50 19 17 16
40–49 19 20 21
30–39 24 24 26
o30 25 28 28
Unknown/missing 13 12 10
Clinical ﬁndings at discharge/after visit
Weight (kg) NA 79 (18) 79 (18)
Systolic blood pressure (mm Hg) 128 128 (21) 128 (21)
Heart rate (beats/min) 75 73 (15) 72 (15)
Hemoglobin (g/L) 132 133 (17) 135 (16)
Creatinine (μmol/L) 112 105 (54) 100 (46)
eGFR (mL/min) 60 64 (26) 66 (26)
Comorbidities (past or present) (%)
Ischemic heart disease 47 44 42
Hypertension 46 49 47
Atrial ﬁbrillation 47 46 45
Valvular heart disease 19 18 17
Dilated cardiomyopathy 11 14 15
Diabetes 24 23 20
Lung disease 18 18 16
Performed procedures (ever) (%)
Cardiac revascularization 24 26 26
Cardiac valvular surgery 5 5 6
Device therapy 13 12 11
Medications at discharge/after visit (%)
ACE inhibitors/ARBs 80 88 91
Beta-blockers 83 87 88
Diuretics 87 76 75
Aldosterone antagonist 21 25 25
Digitalis 18 17 16
Statins 42 50 52
Anticoagulants 35 41 43
Antiplatelets 53 49 47
EQ-5D index value (Swedish value set)
Mean  SD NA 0.828  0.135 0.846  0.126
Median NA 0.868 0.880
Range (min, max) NA (0.340, 0.969) (0.340, 0.969)
EQ-5D index value (UK value set)
Mean  SD NA 0.696  0.302 0.732  0.275
continued on next page
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Table 1 – continued
Variable All patients in
SHFR
Patients with the
EQ-5D at
inclusion
Patients with the
EQ-5D at follow-
up
Median NA 0.743 0.796
Range (min, max) NA (0.594, 1) (0.594, 1)
% of responses at ceiling (either value set) NA 25 27
Notes. Numbers present mean values  SD or proportion, as appropriate. Information on all SHFR patients based on 2010 annual report.
Figures for point of care are not entirely comparable across data sets because of coding differences. The NYHA was rated by a clinician.
Medications refer to 2010 only.
ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; eGFR, estimated glomerular ﬁltration rate; EQ-5D, EuroQol ﬁve-
dimensional questionnaire; LVEF, left ventricular ejection fraction; NA, not available; NYHA, New York Heart Association; SHFR, Swedish Heart
Failure Registry.
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This appears to be the ﬁrst study to analyze determinants of
utility in CHF in a large sample of patients from clinical practice.
We identiﬁed several important drivers of utility at inclusion,
including age, sex, NYHA class, LVEF, hemoglobin, SBP, lung
disease, diabetes, ACE inhibitors/ARBs, beta-blockers, nitrates,
antiplatelets, and diuretics. Change in utility over 1 year among
survivors was inﬂuenced by age, sex, and (measured at inclusion)
disease duration, NYHA class, SBP, ischemic heart disease, lung
disease, ACE inhibitors/ARBs, and antiplatelets.
The interaction in the model between age and NYHA class at
inclusion could be explained by a higher general expected utility
in the youngest age group, and a potential for higher incrementalFig 1 – Distribution of responses by severity level in the EQ-5D
Swedish population (16–84 years), and a comparable age group
reported for 70- to 79-year-olds. EQ-5D, EuroQol ﬁve-dimensionlosses in HRQOL and utility for these patients when they develop
symptoms. Descriptive analyses (results not presented) showed
that anxiety/depression is more negatively affected in the young-
est age group, compared with an otherwise larger proportion of
younger respondents stating no problems in the other
dimensions.
Different methods have been proposed to address the distri-
butional properties of utility data, including Tobit, censored least
absolute deviations, two-part, latent class, and beta models [21–
23,29,30]. Some of the methods tested previously in the literature,
such as Tobit or censored least absolute deviations, have been
criticized for their censoring assumptions [21]. To date, no model
has been found to address all concerns and issues related to
utility data. Therefore, the choice of the model will depend on the
data at hand and the research objectives. For instance, thedimensions, for patients with CHF at inclusion, the general
(70–79 years). Note. Only moderate or severe problems
al questionnaire; CHF, chronic heart failure.
Table 2 – Final model speciﬁcations for determinants of utility at inclusion using the Swedish value set, for OLS and two-part models.
Variable OLS (n ¼ 4147) Two-part: Logistic (n ¼ 3982) Two-part: OLS (n ¼ 2924)
Coefﬁcient 95% CI P Odds ratio 95% CI P Coefﬁcient 95% CI P
Demographic characteristics
Sex: female 0.037 0.045 0.029 0.000 0.597 0.498 0.716 0.000 0.027 0.037 0.018 0.000
Age0: o60 y Reference group Reference group Reference group
Age1: 60–69 y 0.005 0.026 0.016 0.660 0.848 0.468 1.536 0.586 0.006 0.050 0.039 0.796
Age2: 70–79 y 0.023 0.045 0.001 0.041 0.553 0.316 0.966 0.037 0.023 0.065 0.018 0.267
Age3: Z80 y 0.037 0.063 0.011 0.006 0.395 0.212 0.736 0.003 0.031 0.074 0.011 0.149
Disease characteristics
NYHA I Reference group Reference group Reference group
NYHA II 0.068 0.089 0.047 0.000 0.331 0.199 0.551 0.000 0.071 0.109 0.032 0.000
NYHA III 0.150 0.178 0.123 0.000 0.072 0.037 0.140 0.000 0.110 0.151 0.069 0.000
NYHA IV 0.265 0.370 0.161 0.000 0.051 0.006 0.412 0.005 0.179 0.285 0.072 0.001
Age1  NYHA II 0.029 0.002 0.056 0.035 1.342 0.690 2.611 0.387 0.041 0.009 0.090 0.109
Age1  NYHA III 0.042 0.007 0.076 0.017 1.990 0.874 4.534 0.101 0.029 0.023 0.082 0.272
Age1  NYHA IV 0.051 0.069 0.171 0.403 0.000 0.000 0.000 0.000 0.015 0.109 0.139 0.813
Age2  NYHA II 0.042 0.015 0.069 0.003 1.426 0.763 2.667 0.266 0.061 0.015 0.107 0.009
Age2  NYHA III 0.051 0.017 0.085 0.003 3.022 1.391 6.567 0.005 0.037 0.012 0.086 0.136
Age2  NYHA IV 0.054 0.062 0.170 0.362 2.050 0.180 23.399 0.564 0.001 0.117 0.120 0.982
Age3  NYHA II 0.041 0.010 0.072 0.009 1.921 0.960 3.841 0.065 0.052 0.005 0.100 0.031
Age3  NYHA III 0.068 0.032 0.105 0.000 2.674 1.148 6.227 0.023 0.058 0.008 0.107 0.022
Age3  NYHA IV 0.086 0.025 0.196 0.130 0.745 0.041 13.636 0.843 0.038 0.076 0.152 0.513
LVEF Z50% Reference group Reference group Reference group
LVEF 40%–49% 0.016 0.004 0.028 0.008 1.439 1.105 1.873 0.007 0.008 0.005 0.022 0.204
LVEF 30%–39% 0.028 0.017 0.040 0.000 1.788 1.379 2.319 0.000 0.019 0.006 0.031 0.003
LVEF o30% 0.031 0.019 0.042 0.000 2.270 1.746 2.950 0.000 0.014 0.001 0.027 0.032
Clinical parameters
Hemoglobin (g/L) 0.000 0.000 0.001 0.000 1.007 1.002 1.012 0.005 0.000 0.000 0.001 0.006
Systolic blood pressure (mm Hg) 0.001 0.000 0.001 0.000 1.008 1.004 1.012 0.000 0.000 0.000 0.001 0.001
Comorbidities
Hypertension NS 0.814 0.691 0.959 0.014 0.006 0.003 0.015 0.189
Lung disease 0.019 0.028 0.009 0.000 0.762 0.614 0.946 0.014 0.016 0.026 0.006 0.003
Diabetes 0.022 0.031 0.013 0.000 0.896 0.737 1.089 0.270 0.025 0.035 0.015 0.000
Performed procedures (ever)
Revascularization NS 0.944 0.783 1.139 0.550 0.014 0.004 0.024 0.006
Medications
ACE inhibitors/ARBs 0.035 0.021 0.049 0.000 1.473 1.081 2.008 0.014 0.032 0.018 0.046 0.000
Beta-blockers 0.014 0.003 0.025 0.013 NS NS
Nitrates 0.019 0.031 0.008 0.001 0.711 0.540 0.937 0.015 0.012 0.024 0.001 0.074
Antiplatelets 0.012 0.019 0.004 0.002 0.884 0.751 1.042 0.142 0.013 0.022 0.004 0.004
Diuretics 0.012 0.021 0.004 0.005 0.803 0.671 0.960 0.016 0.008 0.019 0.002 0.131
Constant 0.759 0.712 0.806 0.000 0.740 0.680 0.800 0.000
Fit statistics
R2 0.235 0.170
Pseudo R2 0.128
ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; CI, conﬁdence interval; LVEF, left ventricular ejection fraction; NS, not signiﬁcant; NYHA, New York Heart Association;
OLS, ordinary least squares.
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Table 3 – Final model speciﬁcations for determinants of utility at inclusion using UK value set, for OLS and two-part models.
Variable OLS (n ¼ 4147) Two-part: logistic (n ¼ 4000) Two-part: OLS (n ¼ 2940)
Coefﬁcient 95% CI P Odds ratio 95% CI P Coefﬁcient 95% CI P
Demographic characteristics
Sex: female 0.077 0.096 0.058 0.000 0.602 0.503 0.720 0.000 0.057 0.078 0.036 0.000
Age0: o60 y Reference group Reference group Reference group
Age1: 60–69 y 0.030 0.079 0.018 0.222 0.803 0.442 1.458 0.471 0.063 0.155 0.028 0.176
Age2: 70–79 y 0.067 0.116 0.018 0.008 0.534 0.306 0.932 0.027 0.078 0.159 0.003 0.060
Age3: Z80 y 0.101 0.159 0.044 0.001 0.368 0.197 0.686 0.002 0.092 0.175 0.009 0.029
Disease characteristics
NYHA I Reference group Reference group Reference group
NYHA II 0.150 0.193 0.107 0.000 0.312 0.187 0.520 0.000 0.162 0.234 0.090 0.000
NYHA III 0.325 0.388 0.262 0.000 0.069 0.036 0.134 0.000 0.232 0.314 0.149 0.000
NYHA IV 0.631 0.875 0.388 0.000 0.050 0.006 0.400 0.005 0.492 0.778 0.206 0.001
Age1  NYHA II 0.088 0.027 0.148 0.004 1.420 0.728 2.772 0.304 0.157 0.055 0.259 0.003
Age1  NYHA III 0.119 0.039 0.199 0.003 2.100 0.919 4.798 0.078 0.125 0.011 0.238 0.031
Age1  NYHA IV 0.159 0.117 0.436 0.259 0.000 0.000 0.000 0.000 0.161 0.159 0.481 0.324
Age2  NYHA II 0.104 0.044 0.163 0.001 1.508 0.807 2.818 0.198 0.168 0.077 0.260 0.000
Age2  NYHA III 0.146 0.068 0.223 0.000 3.111 1.432 6.760 0.004 0.130 0.027 0.232 0.013
Age2  NYHA IV 0.175 0.103 0.453 0.217 2.038 0.179 23.242 0.566 0.106 0.210 0.422 0.510
Age3  NYHA II 0.126 0.059 0.194 0.000 2.108 1.054 4.215 0.035 0.172 0.077 0.266 0.000
Age3  NYHA III 0.192 0.110 0.274 0.000 2.876 1.234 6.701 0.014 0.177 0.074 0.280 0.001
Age3  NYHA IV 0.247 0.019 0.513 0.068 0.802 0.044 14.605 0.881 0.203 0.103 0.510 0.194
LVEF Z50% Reference group Reference group Reference group
LVEF 40%–49% 0.030 0.003 0.057 0.031 1.452 1.116 1.891 0.006 0.011 0.019 0.042 0.463
LVEF 30%–39% 0.064 0.038 0.089 0.000 1.771 1.364 2.299 0.000 0.041 0.012 0.069 0.006
LVEF o30% 0.069 0.043 0.096 0.000 2.250 1.729 2.928 0.000 0.031 0.001 0.062 0.045
Clinical parameters
Hemoglobin (g/L) 0.001 0.000 0.002 0.002 1.007 1.002 1.012 0.006 0.001 0.000 0.001 0.076
Systolic blood pressure (mm Hg) 0.001 0.001 0.001 0.000 1.008 1.005 1.012 0.000 0.001 0.000 0.001 0.008
Comorbidities
Hypertension NS 0.803 0.681 0.946 0.009 0.001 0.020 0.021 0.945
Lung disease 0.032 0.055 0.010 0.005 0.779 0.627 0.967 0.024 0.024 0.049 0.000 0.054
Diabetes 0.040 0.062 0.019 0.000 0.897 0.739 1.090 0.276 0.041 0.065 0.018 0.001
Medications
ACE inhibitors/ARBs 0.075 0.043 0.107 0.000 1.446 1.061 1.971 0.019 0.067 0.034 0.101 0.000
Beta-blockers 0.037 0.011 0.062 0.005 1.219 0.958 1.551 0.107 0.037 0.007 0.066 0.015
Nitrates 0.042 0.069 0.014 0.003 0.691 0.526 0.908 0.008 0.021 0.051 0.009 0.163
Antiplatelets 0.027 0.043 0.010 0.002 0.872 0.747 1.019 0.085 0.024 0.043 0.004 0.016
Diuretics 0.028 0.047 0.009 0.004 0.803 0.672 0.960 0.016 0.017 0.041 0.006 0.142
Constant 0.565 0.458 0.672 0.000 0.522 0.390 0.653 0.000
Fit statistics
R2 0.203 0.136
Pseudo R2 0.128
ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; CI, conﬁdence interval; LVEF, left ventricular ejection fraction; NS, not signiﬁcant; NYHA, New York Heart Association;
OLS, ordinary least squares.
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Table 4 – Predictive accuracy of OLS and two-part models, for Swedish and UK value sets.
Parameter (valuation set) OLS Two-part model
Sweden Mean  SD Min Max Mean  SD Min Max
EQ-5D index 0.835  0.134 0.398 0.969 0.840  0.131 0.398 0.969
Predicted utility 0.837  0.065 0.600 0.977 0.848  0.067 0.625 0.978
Mean SE 95% CI (bs) Mean SE
MAE 0.091 0.004 0.084 0.099 0.088 0.004 0.082 0.097
MSE 0.014 0.001 0.012 0.016 0.013 0.001 0.011 0.016
UK Mean  SD Min Max Mean  SD Min Max
EQ-5D index 0.708  0.307 0.429 1.000 0.720  0.297 0.429 1.000
Predicted utility 0.715  0.136 0.158 0.985 0.721  0.127 0.220 0.960
Mean SE 95% CI (bs) Mean SE
MAE 0.205 0.009 0.188 0.225 0.201 0.009 0.185 0.221
MSE 0.075 0.007 0.063 0.091 0.072 0.007 0.061 0.088
bs, bootstrapped (bias-corrected); CI, conﬁdence interval; MAE, mean absolute error; MSE, mean square error; OLS, ordinary least squares; SE,
standard error.
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 4 3 9 – 4 4 8446problems with signiﬁcance and conﬁdence intervals arising when
using OLS may to some extent be remedied by using robust
standard errors or nonparametric bootstrapping [21], necessitat-
ing correct model speciﬁcation to ensure that the mean is
correctly modeled [22]. We found that the performance for the
OLS and two-part models varied across different age groups and
between value sets. Generally, there was a trend of slightly higher
precision for the two-part model on an individual level and for
the OLS model on a population level. The OLS model consistentlyTable 5 – Final model speciﬁcations for determinants of a
up, using the Swedish value set (N ¼ 2995).
Variable Coefﬁcient
Demographic characteristics
Sex: female 0.000
Age0: o60 y
Age1: 60–69 y 0.005
Age2: 70–79 y 0.004
Age3: Z80 y 0.015
Health status at inclusion
NYHA I
NYHA II 0.015
NYHA III 0.017
NYHA IV 0.091
Disease duration o6 mo 0.015
Clinical parameters at inclusion
Systolic blood pressure (mm Hg) 0.000
Comorbidities at baseline
Ischemic heart disease 0.012
Lung disease 0.014
Medications at baseline
ACE inhibitors/ARBs 0.025
Antiplatelets 0.014
Constant 0.056
Fit statistics
R2 0.030
Note. Example for deriving the change in utility: if a patient had a utility o
change in utility to year 1 would be 0.056; i.e., the utility at 1 y would be
ACE, angiotensin-converting enzyme; ARBs, angiotensin receptor blockecaptured the range of observed utilities to a better degree.
Therefore, in light of our overall objectives, we believe that the
OLS model is a viable primary option for modeling utilities for use
in economic evaluations (where population means are of inter-
est) in this data set, owing to its relative accuracy on a population
level and its ease of implementation.
Our ﬁndings regarding determinants of utility conﬁrm and
expand on previous research in this ﬁeld. For 1628 patients with
CHF and recent acute myocardial infarction enrolled in a clinicalbsolute change in utility from inclusion to 1-y follow-
95% CI P
0.010 0.011 0.933
Reference group
0.012 0.021 0.568
0.012 0.020 0.593
0.033 0.002 0.077
Reference group
0.003 0.027 0.013
0.003 0.031 0.018
0.049 0.134 0.000
0.006 0.025 0.001
0.001 0.000 0.000
0.022 0.001 0.026
0.027 0.001 0.034
0.041 0.008 0.005
0.004 0.025 0.005
0.018 0.093 0.003
f 0.8 at inclusion and all other variables are at the reference level, the
0.8 þ 0.056 ¼ 0.856.
rs; CI, conﬁdence interval; NYHA, New York Heart Association.
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 4 3 9 – 4 4 8 447trial, Gohler et al. [12] developed two separate models for utilities
derived from the EQ-5D based on either the NYHA class or the
number of cardiovascular rehospitalizations during 18 months of
follow-up. Given the multinational nature of the trial, EQ-5D
scores were weighted on the basis of relevant preferences for the
United States, the United Kingdom, and Latin America; results
showed that utilities were highest in the United States. Despite
differences in the populations and methodology, we obtained
similar results regarding age, sex, NYHA class, and comorbidities
(speciﬁcally diabetes and lung disease). In addition to a broader
patient sample and set of variables in our study, we identiﬁed a
signiﬁcant impact of LVEF and different common medications on
utility.
The ﬁnding that the utility for patients with reduced LVEF
was higher than for those with normal LVEF when controlling
for other factors is an important addition to previous studies
that have evaluated HRQOL in reduced versus preserved LVEF.
For example, in a controlled clinical trial setting in the United
States, HRQOL measured with the Minnesota Living With Heart
Failure Questionnaire was not found to be different between the
two patient groups [31], whereas a large cross-sectional retro-
spective study in outpatient care found preserved LVEF to be
independently associated with worse scores on both the Min-
nesota Living With Heart Failure Questionnaire and the EQ-5D
visual analogue scale [11]. Differences in results across studies
may be due to variations in the underlying patient samples,
study settings, measurement of HRQOL and utility, as well as
analytical techniques. This is an area that warrants further
research.
Using our OLS model based on the UK value set (to allow
comparisons with previous research), the utilities for, for example,
male patients with CHF aged 70 to 79 years (with all other variables
at the reference level) were found to be 0.50 for NYHA class I, 0.45
for class II, 0.32 for class III, and 0.04 for class IV. In the same
patient group, the utility for CHF with preserved ejection fraction
(LVEF Z50%) would be 0.50 versus 0.56 to 0.57 for CHF with
reduced ejection fraction (LVEF o 40%). Although the evidence
around minimum clinically important differences for the EQ-5D is
heterogeneous [32], analyses based on instrument-deﬁned health
transitions indicate a mean minimally important difference of 0.08
for the EQ-5D for the UK value set and 0.04 for the US value set
(which produces a more narrow range of utilities) [33]. This is in
line with earlier results [34], and indicates that our model based on
a generic HRQOL instrument is capable of capturing clinically
important differences between patient groups similar to what has
been observed in other studies [12,35].
There are several limitations to our study. First, our sample
presents a selected subgroup of patients who completed the EQ-5D
at inclusion in the SHFR. These patients differ from the overall
SHFR population in that they were slightly younger, more often
male, less often in NYHA class IV, and received somewhat differ-
ent medications. These differences may be due to a larger
proportion of patients in our sample stemming from an outpatient
setting. Of note, patients captured by the SHFR may not be fully
representative of the general CHF population in Sweden because
the reporting from primary care is limited [16]. Moreover, com-
pared with a large population-based sample of patients with heart
failure in Sweden from 2010 [3], which also included acute disease,
patients in the SHFR were slightly younger (75 vs. 77 years), more
often men (61% vs. 49%), and less frequently had ischemic heart
disease (47% vs. 51%), hypertension (46% vs. 71%), and diabetes
(24% vs. 27%), but more often atrial ﬁbrillation (47% vs. 45%).
Therefore, our sample is likely not representative of patients in the
oldest age groups, all women (which may be related to age), those
in NYHA IV, or those managed only in primary care. This could
imply an overestimation of utilities in the overall CHF population
due to representation in terms of age, sex, and functional class,and potentially an underestimation due to a predominant inclu-
sion from hospitals. The possible impact of differences in comor-
bidities, however, is difﬁcult to estimate. Although we have
adjusted for the known confounders in our analyses, the results
inherently do not capture unobserved confounders.
Second, our analyses of drivers of utility evolution over time
are limited by the lack of comprehensive information in the SHFR
on changes in clinical parameters and events following inclusion
in the registry. In addition, there was a considerable loss to
follow-up (34%), which partly is due to a high (19%) 1-year
mortality [16] and the progressive nature of CHF.
Finally, the utilities are based on a generic HRQOL instrument,
which inherently is not as responsive to clinical changes as
disease-speciﬁc instruments [36,37]. Despite this and a marked
ceiling effect, our analyses indicate that it was possible to capture
clinically relevant differences in utilities derived from the EQ-5D
at inclusion, for example, in terms of NYHA class or LVEF.
Moreover, the usefulness of generic HRQOL instruments in CHF
has been suggested by a large study investigating drivers of
HRQOL in outpatients with CHF [11]; determinants were found
to be similar when analyzing scores from the EQ-5D visual
analogue scale and the Minnesota Living With Heart Failure
Questionnaire as separate outcomes variables.
Notwithstanding these limitations, our analysis has several
important strengths. It is based on the largest and most
comprehensive sample of patients with CHF to date, covering
5334 patients treated in inpatient and outpatient care. Because
of its size and the amount of variables available, it also provides
new information on several important subgroups, for example,
age, sex, and patients with preserved or reduced LVEF. The focus
on a large number of patients with CHF allows for robust
estimations regarding variables that are of importance in this
population.
From a methodological point of view, we performed compre-
hensive statistical testing, for example, checking for interaction
terms and nonlinearity, and compared different modeling
approaches commonly discussed in the literature using within-
sample validation. In this context, further research including out-
of-sample validation could be of value. Moreover, we present
models for estimating utilities in CHF based on two different
value sets, which represent both different geographies and
valuation methods. Value sets differ between countries because
of not only methodological variances but potentially also cultural
differences [38]. There is considerable debate and a heteroge-
neous body of evidence regarding whether experience-based or
hypothetical values are to be preferred (e.g., [6,39]). Generally,
experience-based values may include adaptation and tend to be
higher than hypothetical values, especially for severe health
states [6]. Thus, our study provides a comparison and choice
between two different approaches and sources, which can be
tailored to the decision context.Conclusions
In this large study of patients with CHF in clinical practice, we
have identiﬁed a range of demographic and clinical factors that
inﬂuence utility, both at inclusion and over time. The ﬁndings
can be used to target clinical interventions and in economic
evaluations of new therapies for patients with CHF. Overall, we
found that the OLS model addressed our research objective
adequately and we provide results for both the Swedish and UK
value sets.
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